NATIONAL CANCER CENTER;GENE TECHNO SCIENCE CO., LTD.;THEORIA Science Inc.
发明人:
Takahiro Ochiya,Naoomi Tominaga
申请号：
US15552766
公开号：
US20180274035A1
申请日:
2015.02.24
申请国别(地区):
US
年份:
2018
代理人:
摘要：
A purpose of the present invention is to provide a diagnosis and risk evaluation method for cancer brain metastasis and a treatment and prevention method therefor by clarifying the mechanism of blood-brain barrier (BBB) disruption in brain metastasis. Another purpose of the present invention is to provide a drug delivery system to the brain. Still another purpose of the present invention is to provide a medicine, composition and kit to be used in these methods. Therefore, the present invention relates to a method for diagnosing brain metastasis or evaluating the risk of the occurrence of brain metastasis. The method includes the step of determining miR-181c level in a specimen. Further, the present invention relates to a method for treating or preventing brain metastasis. The method includes the step of inhibiting the expression or activity of miR-181c in a cancer patient. Furthermore, the present invention relates to a method for improving permeability through BBB with the use of miR-181c or PDPK1 and a method for enabling a desired active ingredient to pass through BBB and reach inside the brain.
